---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-047584"
form_type: "8-K"
ticker: "OVID"
cik: "0001636651"
company_name: "Ovid Therapeutics Inc."
filed_at: "2026-07-08T11:03:56+00:00"
generated_at: "2026-07-08T11:05:06.683356+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Ovid Therapeutics appoints Charles Carter as CFO, replacing Jeffrey Rona

## Summary
- CFO Jeffrey Rona departed July 6, 2026; no disagreement with company on accounting or financial reporting.
- Charles Carter appointed CFO, SVP of Finance since Oct 2024; previously CFO at CERo Therapeutics and iCAD.
- Carter receives $460k base salary, 35% target bonus, 50,000 RSUs vesting over 2 years, plus $75k bonus opportunity.
- Rona receives 12 months base salary severance, prorated 2026 bonus, COBRA for 12 months, and consulting role through Dec 2027.

## SEC filing metadata
- accession: 0001628280-26-047584
- form_type: 8-K
- ticker: OVID
- cik: 0001636651
- company_name: Ovid Therapeutics Inc.
- filed_at: 2026-07-08T11:03:56+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1636651/000162828026047584/0001628280-26-047584-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1636651/000162828026047584/ovid-20260707.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-047584
- JSON: https://secwatch.observer/filing/0001628280-26-047584.json
- Plain text: https://secwatch.observer/filing/0001628280-26-047584.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.